Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Microscopic Polyangiitis (MPA).

Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Guillain-Barre Syndrome.

INR:5186. rummy cash games, fantasy: mpl The overseas rights of Aisen Biopharma's third-generation EGFR-TKI "Avitinib" were ...

INR:4409. 40 kb in pixels width and height The second in China! Hangkang Pharmaceutical's new Category 4 "Parecoxib Sodium ...

INR:7326. slots game earn money Osimertinib's new indication application in China is planned to be included in the priority review Two articles in Cell on t ...

INR:1244. take5 free slots real vegas casino Roche's CD20 monoclonal antibody for membranous nephropathy and Agios' thalassemia therapy were sh ...

dear monthly chart january 2023 Kangfang Biopharma's PD-1/VEGF (AK112) received NMPA clinical trial approval Losing medical insurance support! Ascletis's half-year performance fell 57.8% and R&D ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P. Morgan Healthcare ...

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR ...

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and ...

IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Background: This study evaluated the efficacy of rituximab (RTX) in primary membranous nephropathy (PMN) patients with incomplete remission and drug dependence after long-term use of calmodulin ...